China Biopharmaceutical Co., Ltd. is the pharmaceutical division of the Charoen Pokphand Group in China and a leading innovation-driven pharmaceutical group in the country. 

Its business spans the entire industrial chain of R&D, production, and commercialization of innovative drugs, biological products, and high-end generics, with strong positions in 

four major therapeutic areas: oncology, liver/cardiovascular metabolism, respiratory/autoimmune, and surgical/pain management.  

Driven by the vision of 'focusing on innovation, serving patients, and becoming a global leading pharmaceutical company,' China Biopharmaceutical has built drug R&D and 

production bases centered in Beijing, Shanghai, Guangzhou, Nanjing, and Lianyungang. Its subsidiaries, Chia Tai Tianqing Pharmaceutical Group and Beijing Tide Pharmaceutical Co., Ltd., 

have been ranked among the 'Top 100 Chinese Pharmaceutical Enterprises' for many years. Wholly-owned subsidiaries Lixin Medicine and Hecgenia focus on pioneering innovation through 

self-developed differentiated technology platforms.  

The company has a global R&D team of over 2,900 people and has established cutting-edge technology platforms covering bispecific antibodies, ADCs, PROTACs, small nucleic acids, and more. 

Throught diverse approaches such as independent innovation, international collaboration, and overseas licensing, the company actively integrates global innovative resources and continuously 

expands its international influence.